{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T03:22:46Z","timestamp":1649042566201},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n<jats:sec>\n<jats:title>Hintergrund<\/jats:title>\n<jats:p>M\u00e4nner in Deutschland sterben fr\u00fcher als Frauen und nehmen weniger h\u00e4ufig Krebsvorsorgeuntersuchungen wahr.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Fragestellung<\/jats:title>\n<jats:p>Ziel war die prospektive Evaluation einer \u201eMovember-Gesundheitsinitiative\u201c am Universit\u00e4tsklinikum Frankfurt (UKF) im November 2019.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methoden<\/jats:title>\n<jats:p>Im Rahmen der \u201eMovember-Gesundheitsinitiative\u201c wurde allen m\u00e4nnlichen Mitarbeitern des UKF ab dem 45.\u00a0Lebensjahr und bei erstgradiger famili\u00e4rer Vorbelastung eines Prostatakarzinoms ab dem 40.\u00a0Lebensjahr im November 2019 gem\u00e4\u00df S3-Leitlinien der Deutschen Gesellschaft f\u00fcr Urologie (DGU) eine Prostatakarzinom-Vorsorgeuntersuchung angeboten.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Ergebnisse<\/jats:title>\n<jats:p>Insgesamt nahmen 14,4\u202f% der Mitarbeiter teil. Eine famili\u00e4re Vorbelastung gaben insgesamt 14,0\u202f% Teilnehmer an. Das mediane Alter betrug 54\u00a0Jahre. Der mediane PSA(prostataspezifisches Antigen)-Wert lag bei 0,9\u202fng\/ml, der mediane PSA-Quotient bei 30\u202f%. Bei 5\u202f% (<jats:italic>n<\/jats:italic>\u202f=\u202f6) zeigte sich ein suspekter Tastbefund in der DRU (digital-rektale Untersuchung). Nach Altersstratifizierung (\u2264\u202f50 vs. &gt;\u202f50\u00a0Lebensjahre) zeigten sich signifikante Unterschiede im medianen PSA-Wert (0,7\u202fng\/ml vs. 1,0\u202fng\/ml, <jats:italic>p<\/jats:italic>\u202f&lt;\u202f0,01) und der bereits zuvor durchgef\u00fchrten urologischen Vorsorge (12,1 vs. 42,0\u202f%, <jats:italic>p<\/jats:italic>\u202f&lt;\u202f0,01). Vier Teilnehmer (3,3\u202f%) zeigten erh\u00f6hte Gesamt-PSA-Werte. Bei 32,2\u202f% der Teilnehmer zeigte sich mindestens ein kontrollbed\u00fcrftiger Befund. Insgesamt wurden 6\u00a0Prostatabiopsien durchgef\u00fchrt. Hierbei zeigte sich in einem Fall ein intermediate-risk Prostatakarzinom (Gleason 3\u202f+\u202f4, pT3a, pPn1, pNx, R0).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Schlussfolgerungung<\/jats:title>\n<jats:p>Im Rahmen der UKF-Movember-Gesundheitsinitiative 2019 konnten durch ein Vorsorgeangebot 121\u00a0M\u00e4nner f\u00fcr eine Prostatakrebs-Vorsorge inklusive PSA-Testung gewonnen werden. Auff\u00e4llige\/kontrollbed\u00fcrftige Befunde zeigten sich bei 32,2\u202f%. Bei einem Mitarbeiter wurde ein therapiebed\u00fcrftiges Prostatakarzinom entdeckt und therapiert.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00120-020-01265-y","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T11:26:19Z","timestamp":1593689179000},"page":"1237-1245","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Urologische Prostatakrebsvorsorge im Rahmen der Movember-Gesundheitsinitiative 2019 am Universit\u00e4tsklinikum Frankfurt"],"prefix":"10.1007","volume":"59","author":[{"given":"M.","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Humke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Wicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Engl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Hintereder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. J.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"K\u00f6llermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Asgharie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Theissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Welte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. K. H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Preisser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"issue":"1","key":"1265_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.eururo.2015.08.038","volume":"69","author":"JO Barentsz","year":"2016","unstructured":"Barentsz\u00a0JO, Weinreb\u00a0JC, Verma\u00a0S et al (2016) Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. Eur Urol 69(1):41\u201349. \nhttps:\/\/doi.org\/10.1016\/j.eururo.2015.08.038","journal-title":"Eur Urol"},{"key":"1265_CR2","unstructured":"Catalona WJ, Partin AW, Slawin KM, et\u00a0al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a\u00a0prospective multicenter clinical trial. JAMA. 1998;279(19):1542\u20131547. doi:10.1001\/jama.279. 1542"},{"issue":"1","key":"1265_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1464-410X.2006.06193.x","volume":"98","author":"FK-H Chun","year":"2006","unstructured":"Chun\u00a0FK\u2011H, Perrotte\u00a0P, Briganti\u00a0A et al (2006) Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer. bju Int 98(1):50\u201353. \nhttps:\/\/doi.org\/10.1111\/j.1464-410X.2006.06193.x","journal-title":"bju Int"},{"issue":"11","key":"1265_CR4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"16;280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico\u00a0AV, Whittington\u00a0R, Malkowicz\u00a0SB et\u00a0al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 16;280(11):969\u2013974 (Sep)","journal-title":"JAMA"},{"key":"1265_CR5","unstructured":"(2020) DGU, Positionspapier der Deutschen Gesellschaft f\u00fcr Urologie zum Vorbericht: Prostatakrebsscreening mittels PSA-Test. IQWiG, des, S 19\u20131"},{"issue":"6","key":"1265_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.ypmed.2004.10.021","volume":"40","author":"CE Dub\u00e9","year":"2005","unstructured":"Dub\u00e9\u00a0CE, Fuller\u00a0BK, Rosen\u00a0RK, Fagan\u00a0M, O\u2019Donnell\u00a0J (2005) Men\u2019s experiences of physical exams and cancer screening tests: a\u00a0qualitative study. Prev Med 40(6):628\u2013635. \nhttps:\/\/doi.org\/10.1016\/j.ypmed.2004.10.021","journal-title":"Prev Med"},{"key":"1265_CR7","unstructured":"EAU, Policy Paper on PSA Screening for Prostate Cancer, 2019."},{"key":"1265_CR8","doi-asserted-by":"publisher","unstructured":"Eeles RA, Olama AAA, Benlloch S, et\u00a0al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013;45(4):385\u2013391, 391e1\u20112. \nhttps:\/\/doi.org\/10.1038\/ng.2560","DOI":"10.1038\/ng.2560"},{"issue":"103","key":"1265_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"2018","author":"J Ferlay","year":"1990","unstructured":"Ferlay\u00a0J, Colombet\u00a0M, Soerjomataram\u00a0I et\u00a0al (1990) Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer Oxf Engl 2018(103):356\u2013387. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2018.07.005","journal-title":"Eur J Cancer Oxf Engl"},{"key":"1265_CR10","doi-asserted-by":"publisher","unstructured":"Huang Y, Li Z\u2011Z, Huang Y\u2011L, Song H\u2011J, Wang Y\u2011J. Value of free\/total prostate-specific antigen (f\/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10\u202fng\/mL: A meta-analysis. Medicine (Baltimore). 2018;97(13):e0249. \nhttps:\/\/doi.org\/10.1097\/MD.0000000000010249","DOI":"10.1097\/MD.0000000000010249"},{"key":"1265_CR11","unstructured":"Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Langversion 51 2019 AWMF Regist 043022OL."},{"key":"1265_CR12","doi-asserted-by":"publisher","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M et\u00a0al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10;378(19):1767\u20131777. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1801993\n\n.","DOI":"10.1056\/NEJMoa1801993"},{"key":"1265_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-019-02142-0","author":"JS Khan","year":"2019","unstructured":"Khan\u00a0JS, Papa\u00a0NP, Davis\u00a0NF et\u00a0al (2019) Is Movember synonymous with moustaches or men\u2019s health? An examination of internet search activity for prostate and testicular cancer during the campaign. Ir J Med Sci. \nhttps:\/\/doi.org\/10.1007\/s11845-019-02142-0","journal-title":"Ir J Med Sci"},{"key":"1265_CR14","doi-asserted-by":"publisher","unstructured":"Lakes J, Arsov C. PSA-Screening und molekulare Marker [PSA screening and molecular markers]. Urologe A. 2019;58(5):486\u2013493. \nhttps:\/\/doi.org\/10.1007\/s00120-019-0900-y","DOI":"10.1007\/s00120-019-0900-y"},{"key":"1265_CR15","doi-asserted-by":"publisher","unstructured":"Liu Y, Xiao G, Zhou JW, et\u00a0al. Optimal Starting Age and Baseline Level for Repeat Tests: Economic Concerns of PSA Screening for Chinese Men\u201410-Year Experience of a\u00a0Single Center. Urol Int. 2020;104(3\u20134):230\u2013238. \nhttps:\/\/doi.org\/10.1159\/000503733","DOI":"10.1159\/000503733"},{"key":"1265_CR16","unstructured":"Mottet N, Van den Bergh RCN, Briers E et\u00a0al (2019) Guidelines on Prostate Cancer. Eur Assoc Urol. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2020. ISBN 978-94-92671-07-3"},{"key":"1265_CR17","unstructured":"Movember Foundation. 2016. \nwww.movember.com\n\n."},{"issue":"4","key":"1265_CR18","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.juro.2012.11.153","volume":"189","author":"BB Najari","year":"2013","unstructured":"Najari\u00a0BB, Rink\u00a0M, Li\u00a0PS, Karakiewicz\u00a0PI, Scherr\u00a0DS, Shabsigh\u00a0R, Meryn\u00a0S, Schlegel\u00a0PN, Shariat\u00a0SF (2013) Sex disparities in cancer mortality: the risks of being a\u00a0man in the United States. J\u00a0Urol 189(4):1470\u20131474. \nhttps:\/\/doi.org\/10.1016\/j.juro.2012.11.153","journal-title":"J Urol"},{"key":"1265_CR19","doi-asserted-by":"publisher","unstructured":"Oesterling JE, Jacobsen SJ, Klee GG et\u00a0al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J\u00a0Urol. 1995 Sep;154(3):1090\u20135. \nhttps:\/\/doi.org\/10.1016\/s0022-5347(01)66984-2","DOI":"10.1016\/s0022-5347(01)66984-2"},{"key":"1265_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-020-07413-x","author":"HJ Pantel","year":"2020","unstructured":"Pantel\u00a0HJ, Kleiman\u00a0DA, Kuhnen\u00a0AH, Marcello\u00a0PW, Stafford\u00a0C, Ricciardi\u00a0R (2020) Has National Colorectal Cancer Awareness Month increased endoscopy screening rates and public interest in colorectal cancer? Surg Endosc. \nhttps:\/\/doi.org\/10.1007\/s00464-020-07413-x","journal-title":"Surg Endosc"},{"key":"1265_CR21","doi-asserted-by":"publisher","unstructured":"Preisser F, Theissen L, Wild P et\u00a0al. Implementation of Intraoperative Frozen Section During Radical Prostatectomy: Short-term Results from a\u00a0German Tertiary-care Center. Eur Urol Focus. 2019 Mar 21. pii: S2405-4569(19)30082\u20113. \nhttps:\/\/doi.org\/10.1016\/j.euf.2019.03.007\n\n.","DOI":"10.1016\/j.euf.2019.03.007"},{"issue":"1","key":"1265_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1186\/s12885-018-4769-8","volume":"18","author":"D Schliemann","year":"2018","unstructured":"Schliemann\u00a0D, Donnelly\u00a0M, Dahlui\u00a0M et\u00a0al (2018) The \u201cBe Cancer Alert Campaign\u201d: protocol to evaluate a\u00a0mass media campaign to raise awareness about breast and colorectal cancer in Malaysia. Bmc Cancer 18(1):881. \nhttps:\/\/doi.org\/10.1186\/s12885-018-4769-8","journal-title":"Bmc Cancer"},{"issue":"2","key":"1265_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.eururo.2011.02.040","volume":"60","author":"T Schlomm","year":"2011","unstructured":"Schlomm\u00a0T, Heinzer\u00a0H, Steuber\u00a0T et al (2011) Full functional-length urethral sphincter preservation during radical prostatectomy. EurUrol 60(2):320\u2013329. \nhttps:\/\/doi.org\/10.1016\/j.eururo.2011.02.040","journal-title":"EurUrol"},{"key":"1265_CR24","unstructured":"Statistisches Bundesamt, 2017."},{"key":"1265_CR25","doi-asserted-by":"publisher","unstructured":"Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003;97(6):1528\u20131540. \nhttps:\/\/doi.org\/10.1002\/cncr.11208","DOI":"10.1002\/cncr.11208"},{"key":"1265_CR26","doi-asserted-by":"publisher","DOI":"10.21037\/mhealth.2016.10.02","author":"SK Theiss","year":"2016","unstructured":"Theiss\u00a0SK, Burke\u00a0RM, Cory\u00a0JL, Fairley\u00a0TL (2016) Getting Beyond Impressions: An Evaluation of Engagement with Breast Cancer-related Facebook Content. mHealth. \nhttps:\/\/doi.org\/10.21037\/mhealth.2016.10.02","journal-title":"mHealth"},{"issue":"2","key":"1265_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/10810730.2017.1421730","volume":"23","author":"EK Vraga","year":"2018","unstructured":"Vraga\u00a0EK, Stefanidis\u00a0A, Lamprianidis\u00a0G et\u00a0al (2018) Cancer and Social Media: A Comparison of Traffic about Breast Cancer, Prostate Cancer, and Other Reproductive Cancers on Twitter and Instagram. J\u00a0Health Commun 23(2):181\u2013189. \nhttps:\/\/doi.org\/10.1080\/10810730.2017.1421730","journal-title":"J Health Commun"},{"issue":"10","key":"1265_CR28","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1002\/cncr.23885","volume":"113","author":"J Walz","year":"2008","unstructured":"Walz\u00a0J, Haese\u00a0A, Scattoni\u00a0V et al (2008) Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5\u202fng\/mL and lower. Cancer 113(10):2695\u20132703. \nhttps:\/\/doi.org\/10.1002\/cncr.23885","journal-title":"Cancer"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01265-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-020-01265-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-020-01265-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T09:05:42Z","timestamp":1602234342000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-020-01265-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1007\/s00120-020-01265-y","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"assertion":[{"value":"2 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Wenzel, C.\u00a0Humke, S.\u00a0Wicker, J.\u00a0Mani, T.\u00a0Engl, G.\u00a0Hintereder, T.J.\u00a0Vogl, P.\u00a0Wild, J.\u00a0K\u00f6llermann, C.\u00a0R\u00f6del, S.\u00a0Asgharie, L.\u00a0Theissen, M.\u00a0Welte, L.A.\u00a0Kluth, P.\u00a0Mandel, F.K.H.\u00a0Chun, F.\u00a0Preisser und A.\u00a0Becker geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}